Q-omics provides the consensus-scored ABI3 profile across patient tissues and cancer cell-line models. ABI3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ABI3 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, ABI3 protein abundance shows 24,224 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KICH, and LSCC as cancer lineages where ABI3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABI3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABI3 survival associations across molecular data types. ABI3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABI3 RNA expression–survival associations across cancer types. High ABI3 expression shows unfavorable associations in UVM, but favorable associations in HNSC, KIRC, UCEC, SKCM and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ABI3 RNA expression.
This table summarizes ABI3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ABI3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABI3 shows lower tumor expression in KICH, LUSC, LUAD and COAD and higher tumor expression in KIRC and STAD. The KICH box plot shows higher ABI3 RNA expression in normal versus tumor tissue (log2 FC = −1.822, t-test p < 0.001).
This table shows molecular features associated with ABI3 in patient tissues and cancer cell lines. In patient samples, ABI3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ABI3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
